Eptifibatide

Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation. Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation. It inhibits ADP-induced citrated blood aggregation (IC50 = 0.11-0.22 μg/ml) in vitro and in vivo (IC50 = 52 μg/ml in porcine plasma) . Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.

Product Specifications

CAS Number

188627-80-7

Field of Research

Pharmacology & Drug Discovery

Purity

>98%

Smiles

S1C ([H]) ([H]) [C@@] ([H]) (C (N ([H]) [H]) =O) N ([H]) C ([C@]2 ([H]) C ([H]) ([H]) C ([H]) ([H]) C ([H]) ([H]) N2C ([C@] ([H]) (C ([H]) ([H]) C2=C ([H]) N ([H]) C3=C ([H]) C ([H]) =C ([H]) C ([H]) =C23) N ([H]) C ([C@] ([H]) (C ([H]) ([H]) C (=O) O[H]) N ([H]) C (C ([H]) ([H]) N ([H]) C ([C@] ([H]) (C ([H]) ([H]) C ([H]) ([H]) C ([H]) ([H]) C ([H]) ([H]) /N=C (\N ([H]) [H]) /N ([H]) [H]) N ([H]) C (C ([H]) ([H]) C ([H]) ([H]) S1) =O) =O) =O) =O) =O) =O